NPX 887
Alternative Names: NPX-887Latest Information Update: 21 Feb 2024
At a glance
- Originator NextPoint Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; HHLA2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 22 Jan 2024 Phase-I clinical trials in Solid tumours (Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06240728)
- 07 Dec 2023 NextPoint Therapeutics plans first-in-human phase I clinical trial in Solid tumours in early 2024
- 07 Dec 2023 US FDA accepts Investigational New Drug (IND) application for NPX 887 for phase I clinical trial in Solid tumours